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Large-scale genomic studies promise to advance our understanding of the biology of human cancers and to improve their 
diagnosis, prognostication, and treatment. The analysis and interpretation of genomics studies have faced challenges. The 
retrospective and observational design of many studies has rendered them susceptible to confounding and bias. Technological 
variations and advances have impacted on reproducibility. Statistical hurdles in relating a large number of variables to a small 
number of observations have added further constraints. This review considers the promise and challenge associated with the 
large-scale clinically oriented genomic analysis of human cancer and attempts to emphasize potential solutions.Introduction
While microarray studies have achieved much, the immense 
potential of large-scale genomics research to change the man-
agement of human disease remains to be fully realized. Practical 
constraints are imposed by the cost of genomic studies and dif-
ficulties in obtaining sufficient, well-annotated, and representative 
samples, particularly for human studies. While genomic technolo-
gy is continuously improving in reliability and information content, 
comparing and combining data from different genomic platforms 
remains problematic. Most genomic experiments involve thou-
sands of variables (such as gene expression values) measured 
against tens or, at best, hundreds of cases. False positive results 
and data overfitting are significant problems under these circum-
stances. Despite these challenges, validated findings have been 
made, and the first of these have become commercially avail-
able in some countries (Paik et al., 2004). Here, we provide an 
overview of the many complexities that face large-scale clinically 
oriented cancer genomic studies, with the goal of assisting read-
ers and researchers in understanding and anticipating obstacles. 
We begin by examining the role of confounding and bias in study 
design, discuss technology-related limitations and statistical and 
analytical obstacles, and finish with several clinical considera-
tions. We also provide recommendations for circumventing prob-
lems that have beset previous studies (Table 1).
Study design
The main objectives of most large-scale cancer genomics stud-
ies are to search for new molecular subtypes of cancer (class 
discovery); identify differentially expressed genes between pre-
defined cancer classes, such as short- versus long-term survivors 
(class comparison); or predict membership to predefined cancer 
classes (class prediction) (Golub et al., 1999; Simon et al., 2003). 
Class discovery genomic studies have succeeded in identifying 
several important and reproducible molecular cancer subtypes. 
For example, the work of Perou et al. (1999) has identified several 
molecular subtypes of breast cancer, confirming the long held 
notion that breast cancer is comprised of more than one biological 
entity. These subtypes, with distinct gene expression profiles and 
patterns of oncogene activation or tumor suppressor loss, have 
been validated in independent data sets and correlated to clinical cancer cell 9, May 2006 ©2006 ElsEviEr inc. outcome (Sorlie et al., 2001, 2003). Likewise, class comparison 
studies have generated insights into the molecular relationships 
between other cancer subtypes. One example is the comparison 
of gene expression profiles in ovarian cancers from women with 
inherited BRCA1 and BRCA2 mutations to those with sporadic 
cancer (Jazaeri et al., 2002). It appears that the BRCA-associ-
ated pathways are also involved in sporadic cases of ovarian 
cancer, leading to speculation about the role of genetic and epi-
genetic alterations in BRCA genes and downstream regulators. 
Our own study has been able to compare distinct histological 
subtypes of gastric cancer, highlighting transcriptional differences 
between the intestinal and diffuse histologies (Boussioutas et al., 
2003). Many researchers have attempted to springboard from 
class comparison to class prediction studies in order to develop 
valid molecular profiles with potential clinical applications. One 
class comparison study of histological grade 1 and grade 3 breast 
cancers has led to the identification of a gene expression profile 
that can be used to further classify histological grade 2 tumors 
into high versus low risk of recurrence categories, although the 
results of this study require further validation (Sotiriou et al., 
2006). Despite the successes, challenges have been identified 
that affect all three study designs. Practical constraints in obtain-
ing human cancer tissue have led many genomics studies to use 
a limited number of retrospectively collected samples. Therefore, 
the cases may not have been collected in a standardized fashion, 
and the observations may have been made from uncontrolled 
systems. Under these circumstances, data confounding and bias 
are particularly relevant.
Confounding refers to a factor that distorts the true relation-
ship between the study variables of interest (Potter, 2003). A 
confounder is related to the outcome of interest, yet remains 
extraneous to the study question and is unequally distributed 
among the comparator groups. Confounding is important in can-
cer molecular profiling, especially for class comparison and class 
prediction studies. For example, in a study designed to derive 
a molecular predictor of chemotherapy responders and nonre-
sponders, confounding can occur if other therapeutic modali-
ties (e.g., surgery and radiotherapy) are not equally distributed 
amongst the two groups. In this situation, attributing a difference 
in gene expression to the characteristics of the cancer may be 333
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category Problem Potential solutions
study design issues Bias Prospective design
  randomization (where possible)
  Blinding (where appropriate)
  avoid inappropriate pooling of samples
 confounding complete clinical/pathological annotation
  stratification using known confounders
  Use of prospective study design with structured reporting of key information
array issues reproducibility choose a single molecular platform
  standardization of technical protocols
  Biological and technical repeats
  Make available probe sequences for future reannotation
 cross-platform comparison sequence verification of probes
  removal of misannotated probes from analysis
  Utilize up-to-date version of genome annotation
  Use rank statistics rather than absolute values of gene expression
statistical issues Overfitting internal validation (leave one out cross-validation or split-sample analysis)
  External/independent validation
 Unstable gene lists Multiple permutation of training and test sets
 study power a priori calculation of sample size using available methods
  Post hoc analysis of microarray data may indicate adequacy of sample size
 Data interpretation ranked biological themes
  Gene set enrichment analysis (GsEa)
  in vivo modelinginappropriate. To correct the problem, patients should be bal-
anced for known confounders; however, if the study sample size 
is limited, this may be particularly difficult to do and is likely to 
reduce the number of cases suitable for the analysis even further. 
Still, common confounders such as age, gender, cancer stage, 
tumor histology, and the treatment delivered require correction 
whenever possible. Therefore, having comprehensive clinical 
annotation of the biological samples is highly desirable. Accurate 
annotation can be especially difficult to obtain for archival, or 
ad hoc, sample collections. Retrieval of case histories may help 
to complete the sample annotation; however, if the samples do 
not encompass the full spectrum of the disease under study, or 
were compiled over a period when standards in clinical manage-
ment changed, then generalizability to the present may be limited 
(Ahmed and Brenton, 2005). Given the importance of adequate 
clinical annotation for interpreting genomic studies, it would seem 
useful to develop a set of guidelines for recording a minimum 
clinical data set for human tissue used in microarray experiments, 
similar to the Minimal Information About a Microarray Experiment 
(MIAME) (Brazma et al., 2001) and the Standards for Reporting 
Diagnostic Accuracy (Bossuyt et al., 2003a, 2003b; Novere et 
al., 2005). A recent publication has taken the first steps in this 
direction (McShane et al., 2005).
Bias refers to a systematic difference in the way that study 
cases are handled or analyzed. Given that bias is a function of 
study design, every study should be carefully considered for all 
possible sources of bias at the outset. Some sources of bias are 
already acknowledged in the literature or are relatively easily 
identified. For example, differences in the physical handling and 334 processing of cases and controls can introduce bias and lead to 
erroneous conclusions (Coombes et al., 2005). Technical fac-
tors, such as the time required to conduct an assay, the batch of 
reagents used, and the skill levels of different technicians are all 
possible sources of bias. Pooling of tissues from multiple tissue 
banks to increase the sample size is a common practice; however, 
this may increase heterogeneity and introduce additional biases. 
Conversely, some sources of bias may remain concealed, or the 
magnitude and direction of their effect may be difficult to ascer-
tain (Ransohoff, 2005). Avoiding heterogeneity, randomization of 
processing steps, development of strict inclusion and exclusion 
criteria, systemization of protocols, and blinding of technicians 
to the class assignment of the specimens being handled are all 
valid methods for reducing systematic study bias. An extensive 
review of bias associated with molecular prediction studies has 
recently been published by Ransohoff (2005).
The use of a prospective study design is one of the most 
effective methods for controlling confounding and reducing bias-
es. Investigators can plan in advance the hypothesis to be tested 
and the necessary sample annotation to be collected. In addi-
tion, it allows advance consideration of the required sample size 
(see “False findings, power, and sample size” in the “Statistical 
challenges” section below). And finally, a prospective design can 
ensure that all samples are handled and processed in a standard-
ized fashion to minimize experimental bias. This approach has 
been adopted by the European Organization for Research and 
Treatment of Cancer (EORTC) in designing the Microarray In 
Node-negative Disease may Avoid ChemoTherapy (MINDACT) 
study (see “Clinical utility” section). Inevitably, a prospective cancer cell May 2006
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patient enrolment and adequate clinical follow-up. The use of 
biologic material collected previously, such as during a prospec-
tively designed clinical trial, can be an attractive alternative. While 
some variations of sample handling may have occurred in trials 
not specifically intended for gene expression studies, methods to 
demonstrate standardization and quality control can be applied 
(Simon, 2005). A successful example of this approach is the study 
of Paik et al. (2004). Fixed material from over 600 breast cancer 
cases collected as part of a large National Surgical Adjuvant 
Breast and Bowel Project randomized clinical trial was utilized to 
validate a 21 gene RT-PCR-based molecular profile designed to 
predict clinical outcome in early-stage estrogen receptor-positive 
breast cancer patients.
Molecular platform
At the foundation of large-scale genomics is the ability to synthe-
size high-density microarrays. While high-density arrays can be 
constructed for many different purposes (such as measuring gene 
copy number, or epigenetic modifications, etc.), gene expression 
studies represent the most common use of this technology. Many 
of the problems observed with gene expression profiling apply 
to other large-scale genomic modalities. A variety of microarray 
platforms are available for expression analysis (Hardiman, 2004), 
with differences in the platform design, synthesis (in house versus 
commercial), and probe annotation. As a result, cross-platform 
comparisons of gene expression studies have been difficult. This 
is exemplified by two recent studies in breast cancer (van de 
Vijver et al., 2002; Wang et al., 2005) in which less than half of 
the key genes found to be predictive of distant metastases in 
women with lymph node-negative breast cancer were present 
on both sets of microarrays.
Most direct comparisons of different genomics platforms 
have found considerable variation in gene expression results 
(Bammler et al., 2005; Jarvinen et al., 2004; Kuo et al., 2002; 
Tan et al., 2003), although some exceptions exist (Irizarry et al., 
2005; Larkin et al., 2005). Several factors contribute to the vari-
ation, including differences in the methods of RNA labeling, the 
process of hybridization, data acquisition, data preprocessing 
and normalization (Bammler et al., 2005), errors in probe place-
ment and probe annotation (Carter et al., 2005; Jarvinen et al., 
2004; Mecham et al., 2004a, 2004b), and differences attributed 
directly to the platform design (such as the different hybridization 
properties of cDNA arrays, and long and short oligonucleotide 
arrays) (Jarvinen et al., 2004; Kuo et al., 2002; Tan et al., 2003). 
Also, significant interlaboratory variation has been observed even 
when identical microarray platforms and starting nuclear materi-
als are used (Irizarry et al., 2005). Concordance is highest when 
protocols are standardized and the same molecular platform is 
used, with the best results obtained from commercial platforms 
(Bammler et al., 2005; Dobbin et al., 2005). Comparison of data 
generated on different platforms is facilitated by sequence testing 
of probes, removal of misannotated genes from comparative anal-
yses (Carter et al., 2005; Mecham et al., 2004a), using relative 
rather than absolute gene expression measurements (Irizarry et 
al., 2005; Jarvinen et al., 2004; Larkin et al., 2005), and applying 
improved preprocessing algorithms (Gentleman et al., 2004; Yang 
et al., 2002). In addition, comparisons at the level of biological 
processes, rather than single genes, are more informative and 
reproducible (Bammler et al., 2005). It is anticipated that technical 
variation will decline (Larkin et al., 2005), especially as guidelines cancer cell May 2006 and standard operating procedures for the execution of genomic 
experiments are further developed. Many journals mandate the 
use of the MIAME standard (Brazma et al., 2001) in the reporting 
of microarray experiments. Additional standards to improve repro-
ducibility, sensitivity, and robustness in gene expression analysis 
are being proposed (see http://www.cstl.nist.gov/biotech/work-
shops/ERCC2003/).
The annotation of the human genome is continuously evolv-
ing, and therefore earlier annotations of technical platforms are 
slowly becoming obsolete, adding an additional challenge to 
the cross-platform comparison (Dai et al., 2005). A method for 
updating the annotation of probe sets within a platform, based 
on sequence alignments and specified probe selection, has been 
proposed by Dai et al. (2005). The authors suggest that updating 
probe set annotation should provide more accurate interpretation 
of gene expression data.
Finally, the number of transcripts in the mammalian genome 
is at least one order of magnitude greater than previously esti-
mated because of the presence of alternative splicing and tran-
scription from both strands of DNA (Bertone et al., 2004; Cheng 
et al., 2005; The FANTOM Consortium et al., 2005). A compre-
hensive compilation of splice variants has not yet been created 
(Marshall, 2004), and alternative transcripts have not previously 
been considered in the design of gene expression platforms. It 
is possible, then, that previous attempts at cross-platform com-
parisons have been hampered by a failure to adequately account 
for alternative transcription. Recognizing this, concerted efforts 
to incorporate the entire transcriptome onto a single microarray 
platform are being made.
Statistical challenges
In a typical microarray experiment, hundreds, if not thousands, 
of genes are individually subjected to a statistical test of signifi-
cance. The process of multiple hypothesis testing leads to false 
positive findings, a phenomenon that needs to be controlled with-
out markedly compromising study power. Other statistical chal-
lenges, such as determining sample size, data overfitting, and 
unstable gene lists also require consideration.
False findings, power, and sample size
The false positive rate of a test is associated with the standard 
p value. Invented for testing individual hypotheses, the p value 
requires adjustment for multiple testing in order to avoid abundant 
false positive results. Several approaches, varying in the strin-
gency of the correction for multiplicity, are available (reviewed in 
Pawitan et al., 2005). Adjusting the p value has the potential to be 
overly conservative, resulting in loss of power i.e., low sensitivity, 
or high false negative rate. Therefore, the need for a less con-
servative approach for controlling multiple testing and retaining 
study power led to the derivation of the false discovery rate (FDR) 
(Benjamini and Hochberg, 1995; reviewed in Reiner et al., 2003). 
The FDR is the expected proportion of false discoveries among a 
declared significant result, and several methods of FDR multiple 
testing correction exist (Li et al., 2005).
Four characteristics of microarray experiments determine the 
FDR: (1) the proportion of truly differentially expressed genes, 
(2) the distribution of the true differences, (3) variability, and (4) 
the study sample size (Pawitan et al., 2005). Only sample size is 
under the control of the researcher, and it is of key importance 
in the planning of a microarray experiment. Sample size also 
directly affects the power of a study, that is, the probability of cor-
rectly identifying an effect of the desired (or greater) magnitude. 335
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goals and achieve the defined statistical requirements would be 
determined at the study outset, helping to minimize resource 
waste, and creating a level of certainly about the results.
Several approaches for calculating the sample size of a 
microarray experiment have been described and tailored to 
specific study designs (e.g., class comparison or class predic-
tion, etc.) (Black and Doerge, 2002; Dobbin and Simon, 2005; 
Hwang et al., 2002; Pawitan et al., 2005; Wei et al., 2004; Yang 
et al., 2003). Sample size calculations include several compo-
nents: (1) the variance of individual measurements (associated 
with biological and experimental variation), (2) the magnitude of 
the effect to be detected, and (3) the stringency of the FDR. In 
microarray experiments, the first two components are difficult to 
predict. Estimates of variance can be obtained from prior studies, 
but careful case selection is required to ensure generalizability. 
For small studies, the estimated variance may be particularly 
unreliable, and the usual assumption of normal distribution is 
threatened (Dobbin and Simon, 2005). Iterative procedures to 
overcome limited sample size or statistical methods for inferring 
variance across genes may help to improve the estimation of vari-
ance (Wright and Simon, 2003). Larger sample sizes are required 
if variance is large; therefore, conservative sample size predic-
tions should be based on estimates of variance derived from the 
most highly variable genes (Dobbin and Simon, 2005; Yang and 
Speed, 2002). The magnitude of effect can also be a challenge. 
It may be unknown what minimum change in gene expression is 
required for significant biological effects. There is evidence from 
a class comparison study that subtle, coordinated changes in 
expression levels can be biologically important (Mootha et al., 
2003). If a study size was determined a priori using sound statisti-
cal methods, failure to derive a differential gene list using stand-
ard analytical approaches can suggest that alternative methods, 
such as gene set enrichment analysis (GSEA), may be appropri-
ate (see “Interpreting gene lists” section).
The FDR, and hence sample size, are particularly sensitive 
to the proportion of genes that are truly differentially expressed 
(Dobbin and Simon, 2005). Experimenters may already have an 
idea about the number of differentially expressed genes from 
previous studies. However, if this information is not available, a 
highly conservative assumption can be made, or a pilot study 
(also useful to determine other variance components) can be 
conducted (Yang et al., 2003).
While the methodological details of sample size calculations 
are beyond the scope of this review, several approaches have 
been published, and in some cases software has been made 
publicly available (Pawitan et al., 2005). Researchers are encour-
aged to use the existing methods for sample size determination 
in experimental design. By incorporating sample size calculation 
into microarray experiments, the existing methods can be refined 
and improved, increasing further our ability to reliably design and 
analyze large-scale genome studies.
Data overfitting
When thousands of gene transcripts are measured in the devel-
opment of a molecular classifier, there is a substantial chance that 
random associations between genes and the predefined classes 
of interest can occur (Simon et al., 2003). Such data “overfit-
ting” is by definition random and nonreproducible (Lahad et al., 
2005; Ransohoff, 2004; Simon et al., 2003). A good example of 
data overfitting is provided by Simon et al. (2003), who invented 
imaginary cases, ten with and ten without cancer, and a data set 336 containing 6000 genes. The researchers were able to use stand-
ard research methods to generate models, at a high frequency, 
that perfectly fit the training set. Given the entirely arbitrary nature 
of the data, this finding underscores the potential impact of data 
overfitting.
Data overfitting can be reduced if the training set is subjected 
to a rigorous internal cross-validation (Simon et al., 2003). Cross-
validation tests the model building process by removing one (e.g., 
leave one out cross-validation) or more samples out of the training 
set and scoring the ability of the prediction model, derived at each 
iteration, to classify the left-out samples. After the entire training 
set has been examined, a combined model is generated and the 
cross-validated model is reported with an estimate of the pre-
diction error. The error rate can be significantly underestimated 
if investigators fail to account for all specimens (such as those 
that remained unclassified) or if cross-validation is improperly 
conducted (Simon et al., 2003). It is imperative that all aspects of 
the predictive model be subjected to the cross-validation proce-
dure, meaning that for each iteration, the selection of informative 
genes, the computation of the gene weights, and the creation of 
the prediction rule should be repeated.
Once proper internal validation has been completed, the 
predictive model can be subjected to external validation using 
an independent test set. This is key to determining whether data 
overfitting has occurred (Ransohoff, 2004). Independent valida-
tion can involve a split-sample methodology, where some sam-
ples are used to generate the model (training) and others for 
testing the model (validation) (Ransohoff, 2004), or where the 
entire initial data set is used for building a classifier, and then this 
is tested on an independent data set. The latter method requires 
that the validation set comprises cases similar to those for which 
the classifier was designed (Simon, 2005; Simon et al., 2003). 
For example, a two-gene prognostic classifier for the prediction 
of disease recurrence in women with breast cancer (Ma et al., 
2004) could not be validated in an independent data set (Reid 
et al., 2005), likely due to mismatched patient characteristics 
(Simon, 2005). Whenever a test and training set design is used, 
it is essential that complete separation of the samples compris-
ing the sets is achieved to avoid overestimation of the prediction 
accuracy (Ntzani and Ioannidis, 2003; Simon et al., 2003). An 
early genomic study for the prediction of breast cancer recurrence 
(van de Vijver et al., 2002) is notable for incompletely separating 
the test and training sets (Ransohoff, 2004). Finally, it is important 
to note that small test and validation sets are unlikely to represent 
the heterogeneity of the condition under study, and the perform-
ance of the classifier can be markedly overestimated (Ransohoff, 
2004; Simon et al., 2003).
Unstable gene lists
In a classic gene expression study, where thousands of genes 
are being tested against a relatively small set of cancer classes, it 
is possible that multiple and interchangeable gene combinations 
may simultaneously correlate to the classes of interest. Several 
class prediction studies have derived minimally overlapping, 
equally predictive, and valid gene lists (van ’t Veer et al., 2002; 
Wang et al., 2005). While factors such as discrepant genomic plat-
forms, confounding, and bias may contribute to such differences, 
other factors associated with sample composition may also play 
a role. Gene lists derived from a single data set have been found 
to be highly dependent on the composition of the training and test 
sets, displaying “instability” when the training and test sets are 
iterated (Ein-Dor et al., 2005; Michiels et al., 2005). The coinci-cancer cell May 2006
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gene expression (i.e., not representative of the entire population 
from which they were drawn) into the training set may contribute 
to this phenomenon. While, for class prediction, several gene lists 
may be operationally interchangeable, unstable gene lists may 
pose some challenges for studies aimed at gaining insight into 
the underlying biology of different cancer classes. One method 
for reducing gene list instability involves multiple training/test 
set partitions to find the most stable gene list (Michiels et al., 
2005). When an inference about biological processes is desired, 
it may be more appropriate to interrogate the list for biological 
themes present in the data, rather than for individual genes (see 
“Interpreting gene lists”).
Interpreting gene lists
A major goal of any microarray study is to identify biologically or 
clinically significant changes in gene expression. However, some 
analytical approaches may ignore genes that do not pass the 
threshold for differential expression (typically defined arbitrarily).
Also, some biological processes exhibit only subtle, coordinated 
changes in the expression of single genes or groups of genes, 
such that they would not be identified through common analyti-
cal methods.
Methods for identifying and ranking biological themes from 
large-scale genomic data have been developed (e.g., DAVID, 
CLENCH, eGOn, GOstat, Onto-Miner, Avadis, etc.) (listing avail-
able at http://www.geneontology.org/GO.tools.shtml). Such post 
hoc analyses help to identify statistically significant occurrences 
of biologically relevant themes or phrases. While accessible and 
user friendly, all such software contain biases related to the use 
of only the top ranking genes to identify pathway membership and 
from dependence on published abstracts, such that publication 
bias may skew the results.
Searching for significant differences in expression of an a 
priori defined gene set, generated by incorporating biological 
knowledge, may facilitate the detection of modest but coordinate 
changes in sets of functionally related genes. One example of this 
approach is the GSEA, which was initially developed for the com-
parative study of muscle from patients with normal glucose toler-
ance, impaired glucose tolerance, and type II diabetes mellitus in 
whom differentially expressed genes could not be obtained using 
classic approaches (Mootha et al., 2003; Subramanian et al., 
2005). When 149 a priori defined gene sets were tested using the 
GSEA approach, a group of coordinately downregulated genes 
was identified. The results were felt to be biologically plausible 
and have since been independently validated (Patti et al., 2003; 
Petersen et al., 2004). While it is possible that GSEA may be 
biased toward gene sets of larger size (Damian and Gorfine, 
2004), it represents an important advancement in identifying bio-
logical processes from microarray data.
Several groups have successfully examined biological themes 
by integrating multiple independent data sets (Ramaswamy et 
al., 2003; Rhodes et al., 2004; Segal et al., 2004). Rather than 
focusing on ranked gene lists, computational techniques have 
been applied to identify common themes (or unique molecular 
“modules”) underlying human malignancies (Segal et al., 2004, 
2005; Segal et al., 2003). In addition, controlled in vitro and in 
vivo model systems with clearly defined molecular derangements 
have been used to deconvolute and define the molecular signa-
tures of several key activated oncogenes (Huang et al., 2003; 
Lamb et al., 2003; Sweet-Cordero et al., 2005). An important cancer cell May 2006 observation is that oncogene signatures can be detected within 
human cancers and associated with disease outcomes (Bild et 
al., 2005; Glinsky et al., 2004, 2005). It is thought that these types 
of approaches will increase the likelihood of understanding the 
signals in microarray data and will provide results that are more 
interpretable than traditional gene lists (reviewed in Segal et al., 
2005).
Clinical utility
The true test of a predictive profile, and its ultimate acceptance 
as a prognostic tool, requires a demonstration of its utility in the 
clinical setting. For many cancers, prognostic models based on 
clinicopathological factors already exist, and a genomic classifier 
should demonstrate added benefit beyond the best prognostic 
models already in use today. An example of this approach is the 
work of Rosenwald et al. (2002) in patients with diffuse large-B 
cell lymphoma who were treated with standard chemotherapy 
and whose prognosis was determined using the International 
Prognosis Index (IPI). When their molecular profile was incorpo-
rated into the IPI, the survival curves for the patients were fur-
ther split, suggesting that the molecular profile further improved 
predictive ability. While such evidence is compelling, the ideal 
approach would be to demonstrate the added utility of a molecular 
predictor in the setting of a prospectively conducted randomized, 
controlled trial. The MINDACT study in breast cancer patients is a 
randomized clinical trial that incorporates the 70-gene predictive 
profile of Van’t Veer et al. (van de Vijver et al., 2002; van ’t Veer et 
al., 2002) with standard clinical pathological criteria. The study will 
randomize women with discordant molecular and clinicopatho-
logical risk to either receive chemotherapy or not. This design 
will help to determine whether patients with a low-risk molecular 
prognosis but a high-risk clinical prognosis can be safely spared 
adjuvant chemotherapy, thereby avoiding overtreatment of a 
potentially low-risk group of patients.
Conclusion
The identified challenges of large-scale cancer gene expression 
microarrays can, for the most part, be anticipated and managed. 
A multidisciplinary approach to the design of large-scale genomic 
studies, incorporating the expertise of clinicians, scientists, bio-
informaticians, clinical epidemiologists, and statisticians will help 
to address many of the study design, technical, statistical, and 
analysis hurdles outlined in this review. The immense power of 
genomic research is yet to be fully uncovered. By optimizing the 
design and use of gene expression microarrays, and related tech-
nologies, the potential to change the way in which we understand 
and manage human cancers, and many other human diseases, 
may be realized.
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